General
Preferred name
RUFINAMIDE
Synonyms
1H-1,2,3-triazole-4-carboxamide, 1-((2,6-difluorophenyl)methyl)- ()
CGP 33101 ()
E 2080 ()
RUF 331 ()
rufinamide (oral suspension) ()
CGP 33101,E 2080,RUF 331,Banzel ()
60231/4 ()
Rufinamida ()
E2080 ()
E-2080 ()
RUF-331 ()
CGP-33101 ()
Inovelon ()
Banzel ()
Rufinamide-15N-d2 ()
P&D ID
PD002724
CAS
106308-44-5
1795037-48-7
Tags
available
drug
Approved by
FDA
EMA
First approval
2007
Drug indication
Seizure
Epilepsy
Pediatric lennox-gastaut syndrome
Seizure disorder
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ABSORPTION
The oral suspension and tablet are bioequivalent on a mg per mg basis. Rufinamide is well absorbed but the rate is slow and the extent of absorption decreases as dose is increases. Based on urinary excretion, the extent of absorption was at least 85% following oral administration of a single dose of 600 mg rufinamide tablet under fed conditions.; Bioavailability= 70%-85% (decreases with increasing doses); ; Tmax, fed and fasted states= 4-6 hours; ; Cmax, 10 mg/kg/day= 4.01 µL/mL; ; Cmax, 30mg/kg/day= 8.68 µL/mL;; AUC (0h-12h), 10mg/kg/day= 37.8±47 µg·h/mL; ; AUC (0h-12h), 30mg/kg/day= 89.3±59 µg·h/mL.
DESCRIPTION
Rufinamide is a triazole (a heterocyclic compound with molecular formula C2H3N3) derivative anticonvulsant drug.
(GtoPdb)
DESCRIPTION
Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na+ current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome[1][2][3].
PRICE
29
DESCRIPTION
Blocker of KV1.3 and KV1.4 channels
(Tocris Bioactive Compound Library)
DESCRIPTION
Broad-spectrum anticonvulsant.
(LOPAC library)
DESCRIPTION
Rufinamide is an antiepileptic drug used as adjunctive therapy to treat seizures associated with Lennox-Gastaut Syndrome.
(Enamine Bioactive Compounds)
DESCRIPTION
Rufinamide (E 2080), a triazole derivative, is used as voltage-gated sodium channel blocker for the treatment of seizure disorders.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
25
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
LOPAC library
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
42
Molecular Weight
238.07
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
3
Ring Count
2
Aromatic Ring Count
2
cLogP
0.7
TPSA
73.8
Fraction CSP3
0.1
Chiral centers
0.0
Largest ring
6.0
QED
0.85
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
Unknown molecular target
voltage-gated sodium channel blocker
Target
Sodium channel alpha subunit
Sodium Channel
GRM5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A
Primary Target
Voltage-gated Sodium (NaV) Channels
Indication
seizures
Pathway
Membrane Transporter/Ion Channel
Source data
